TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00303667
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously (IV) 50 mg/kg on Days -16 and -15
Study: NCT02610920
Drug: Iron tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
Study: NCT02944474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching lucerastat capsules
Study: NCT04667247
Drug: FoTv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 capsules three times a day for 14 consecutive days.
Study: NCT02521077
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 g ascorbic acid dissolved in 500 ml sterile water.
Study: NCT02135965
Drug: 100mg of Caffeine
Normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of caffeine on metabolic rate
Study: NCT02135965
Drug: 200mg of Caffeine
Normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg of Caffeine on metabolic rate
Study: NCT02135965
Drug: Albuterol 2mg & Caffeine 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 2mg and 100mg of Caffeine
Study: NCT02135965
Drug: Albuterol 2mg and Caffeine 200mg
Normalized name: albuterol 2 MG
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 2mg and Caffeine 200mg on metabolic rate
Study: NCT02135965
Drug: Albuterol 4mg and Caffeine 100mg
Normalized name: albuterol 4 MG
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate
Study: NCT02135965
Drug: Albuterol 4mg and Caffeine 200mg
Normalized name: albuterol 4 MG
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate
Study: NCT03016338
Drug: TSR-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
Study: NCT03349359
Drug: HIV antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
Study: NCT01690975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - single dose at start of each treatment period
Study: NCT04206228
Drug: Intravenous iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min).
Study: NCT04206228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
Study: NCT01298778
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
Study: NCT01037582
Drug: NN9924 (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Study: NCT01037582
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
Study: NCT01037582
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive a single dose of placebo.
Study: NCT01057927
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 capsules 2x100mg BID for 28 days
Study: NCT01057927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
Study: NCT00632086
Drug: PA32540
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02562417
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191007
Drug: Calcipotriol Betamethasone ointment and Urea Cream
Normalized name: betamethasone Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00052026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered twice daily for 8 months
Study: NCT02516423
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV
Study: NCT02162355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 matching placebo tablets once daily for 10 days
Study: NCT03794518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Beta blockers, ACEI, ARB, and aldosterone )
Study: NCT02761213
Drug: 2-L PEG/Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
Study: NCT02062034
Drug: Combined antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
Study: NCT02062034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
Study: NCT03562481
Drug: 1% Buffered Lidocaine 1:100,000 Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
Study: NCT03562481
Drug: 2% Unbuffered Lidocaine 1:100,000 Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
Study: NCT03407521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02664441
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly placebo injections
Study: NCT02171390
Drug: Testosterone 250mg injection
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The testosterone 250mg ester intramuscular injections performed in three weeks
Study: NCT02171390
Drug: Testosteron 50 mg transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg testosterone gel implemented on every night
Study: NCT02336620
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Study: NCT00864617
Drug: ADALAT® CC Extended Release Tablets 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
Study: NCT00128934
Drug: levonorgestrel/ethinyl estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02946684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study: NCT02470117
Drug: Alginate-based reflux suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03380520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nacl 0.9%
Study: NCT03694808
Drug: Fluad Vaccine
Normalized name: Fluad 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: single adjuvanted dose (AD) intramuscular injection
Study: NCT03694808
Drug: Fluzone HD Vaccine
Normalized name: Fluzone 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: single high dose (HD) intramuscular injection
Study: NCT00388895
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00118378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Study: NCT00419549
Drug: Valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single parenteral administration
Study: NCT02277704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01197417
Drug: Intravenous Magnesium Sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
Study: NCT02560974
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
Study: NCT02516410
Drug: Placebo (matched to ivacaftor)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01252719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Study: NCT01328236
Drug: Liposome doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study: NCT01471899
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets every 8 hours for 4 days
Study: NCT00418522
Drug: Inhaled Insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Study: NCT01387425
Drug: placebo tablet is made of lactose
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo at a dose of 1 mg twice for 12 week
Study: NCT02695719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone placebo-matching capsules
Study: NCT04357613
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800mg/d during 14days
Study: NCT04109313
Drug: LOU064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
Study: NCT00006108
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01279252
Drug: metronidazole, clarithromycin, ciprofloxacin and lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02936687
Drug: ET-1 Inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
Study: NCT02936687
Drug: NOS Inhibition Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be infused at the same rate and quantity as the corresponding drug visit.
Study: NCT02936687
Drug: ET-1 Inhibition Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
Study: NCT04691375
Drug: PY314
Normalized name: Pyridoxine
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of PY314 as a single agent given in a standard 3+3 design.
Study: NCT01552967
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles.
Study: NCT02231424
Drug: Drug: Berodual®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04429334
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01389934
Drug: levo-bupicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
Study: NCT01389934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women of this group be infused saline 2 ml / h for 48h.
Study: NCT01173913
Drug: ModraDoc001 10mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-daily administration. One cycle will last 7 days
Study: NCT01173913
Drug: ModraDoc003 10mg tablets and ModraDoc004 10/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
Study: NCT01173913
Drug: ModraDoc006 10 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-daily administration. One cycle will last 7 days
Study: NCT00567736
Drug: Disci/Rhus toxicodendron comp.®
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Study: NCT00567736
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Study: NCT00811434
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml sugar water/kg day for three months
Study: NCT00289003
Drug: Soluble beta-1,3/1,6-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353652
Drug: Study #1: spironolactone (SP), titrated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
Study: NCT00353652
Drug: Study# 2 chlorthalidone (CTD), fixed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
Study: NCT00353652
Drug: Study# 2 spironolactone (SP), fixed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
Study: NCT00353652
Drug: Study# 2 irbsesartan (IR), fixed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
Study: NCT01784666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Study: NCT04284514
Drug: AKB-9778 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKB-9778 Ophthalmic Solution
Study: NCT04284514
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched vehicle-control
Study: NCT04626752
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/㎡ for D-3 and D-2
Study: NCT03026907
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Study: NCT03026907
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
Study: NCT00431275
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-675,206 15 mg/kg iv single dose on Day 1
Study: NCT00004175
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004175
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02225665
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
Study: NCT04595916
Drug: Polyene phosphatidylcholine injection 930 mg QD
Normalized name: dimyristoyl phosphatidylcholine
DrugBank: DL-dimyristoylphosphatidylcholine (DB11283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Study: NCT05378919
Drug: Fluorouracil/folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
Study: NCT05378919
Drug: Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
Study: NCT04247984
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
Study: NCT04537767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00536601
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02502734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study: NCT02070692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day course of placebo during an episode of irregular vaginal bleeding
Study: NCT04487743
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study: NCT03357081
Drug: CEUS or Contrast enhanced Ultrasound
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
Study: NCT00000476
Drug: digitalis
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01638650
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: in accordance with current clinical HIV treatment guidelines
Study: NCT00004997
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02581878
Drug: BAY1862864
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Study: NCT04392557
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin / Alogliptin/ Pioglitazone
Study: NCT04131231
Drug: microparticles packaging methotrexate (MPs-MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50ml, intrapleural infusion, day5,6,7,8
Study: NCT03138681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is given intravenously twice a day for 14 days
Study: NCT03138681
Drug: ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP (100mg) is given intravenously twice a day for 14 days
Study: NCT03560687
Drug: Sucrosomial Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: CardioSideral 2 caps per day
Study: NCT00005622
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
Study: NCT01355159
Drug: Folic Acid 4 mg
Normalized name: multivit,min17/iron/folic acid 4 mg-0.3 mg ORAL TABLET,DISINTEGRATING
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid